|
Dec 03, 2018
|
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
U.S. launch scheduled for early in the first quarter of 2019 Catalyst is well-capitalized and sees no current need for capital infusion CORAL GABLES, Fla. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on
|
|
|
Nov 29, 2018
|
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
- First evidenced-based medicine approved to treat LEMS - Catalyst Pathways™ designed to facilitate access to Firdapse® and provide dedicated patient support - Launch early in the first quarter of 2019 - Catalyst to hold conference call on December 13, 2018 at 8:30 AM ET to discuss launch details
|
|
|
Nov 27, 2018
|
Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review
FDA PDUFA goal date remains tomorrow, November 28, 2018 CORAL GABLES, Fla. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company’s new drug application
|
|
|
Nov 07, 2018
|
Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic
|
|
|
Oct 31, 2018
|
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018
CORAL GABLES, Fla. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
Sep 20, 2018
|
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
|
|
|
Aug 29, 2018
|
Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
|
|
|
Aug 20, 2018
|
Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development
|
|
|
Aug 07, 2018
|
Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
|
|
|
Aug 06, 2018
|
Catalyst Pharmaceuticals Expands Commercial Leadership Team
|
|
